olivLaw · European equity research
Hemogenyx Pharmaceuticals plc HEMO.L
United Kingdom · London Stock Exchange · ISIN GB00BQVXM815 · Vertical: Listed companies from United Kingdom
Hemogenyx Pharmaceuticals plc is a London-listed biotechnology company developing products for acute myeloid leukaemia, blood disorders and viral infections, with its main laboratory in New York. The company has no commercial sales yet, and its net loss for 2024 was 5.6 million pounds sterling.
At the close of 05 Nov 2026, Hemogenyx Pharmaceuticals plc (HEMO.L) stock was 5.85 GBP (−3.31% on the day), with beta 0.37, 52-week range 4.13–11.45 GBP.
Data as of · AI analysis dated · Source: ESEF annual reports and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 44.3
- weak (30–45)
- Bollinger (20, 2)
- 5.64 – 7.86
- in the lower half of the band · %B 0.10 · band width 32.9%
- SMA 50 / 200
- 5.79 / 7.54
- mixed trend
- MACD (12, 26, 9)
- 0.02 / 0.19
- MACD below signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | EURO STOXX 50 | vs EURO STOXX 50 | Vertical median | |
|---|---|---|---|---|
| 1 month | −15.2% | −0.6% | −14.6 pp | — |
| 3 months | −9.2% | −4.2% | −5.0 pp | — |
| 6 months | −16.4% | +4.3% | −20.8 pp | — |
| Year to date | +2.3% | +7.5% | −5.2 pp | — |
| 1 year | −31.7% | +9.9% | −41.6 pp | +5.8% |
| 3 years | −29.5% | +49.8% | −79.4 pp | +26.3% |
| 5 years | −20.1% | +42.8% | −62.9 pp | — |
Price returns, dividends excluded.
Quarterly results
ESEF annual reports carry no quarters: the results are annual (below).
E/P over time
EPS unavailable in the issuer's structured filings (e.g. a partnership reports per unit, not per share).
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Revenue YoY | unavailable | unavailable | unavailable |
| Net income | -4.0 m | -6.7 m | -5.6 m |
| Net income YoY | unavailable | unavailable | unavailable |
| Diluted EPS | unavailable | unavailable | unavailable |
| Diluted EPS YoY | unavailable | unavailable | unavailable |
| net % | unavailable | unavailable | unavailable |
| Free cash flow | -3.3 m | -6.2 m | -4.2 m |
Balance sheet & financial health
Fiscal year 2024 · 31 Dec 2024
- Cash
- 159.3 k GBP
- Financial debt
- unavailable GBP
- Net debt
- unavailable GBP
- Equity
- 853.5 k GBP
- Total assets
- 4.2 m GBP
- Debt / equity
- unavailable
- Current ratio
- 0.72x
- ROE
- -309.2%
- ROA
- -108.9%
- FCF margin
- unavailable
Financial statements (source on every figure)
Revenue and net income (GBP)
Income statement · GBP
| Line | 2022 | 2023 | 2024 | Source (latest year) |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | esef· 27 May 2025verified |
| Operating income | -4.0 m | 6.5 m | 5.4 m | esef· 27 May 2025verified |
| Interest expense | 33 | 316.0 k | 271.6 k | esef· 27 May 2025verified |
| Pre-tax income | -4.0 m | -6.7 m | -5.6 m | esef· 27 May 2025verified |
| Income tax | 0 | 0 | 0 | esef· 27 May 2025verified |
| Net income | -4.0 m | -6.7 m | -5.6 m | esef· 27 May 2025verified |
Balance sheet · GBP
| Line | 2022 | 2023 | 2024 | Source (latest year) |
|---|---|---|---|---|
| Cash | 2.5 m | 1.2 m | 159.3 k | esef· 27 May 2025verified |
| Receivables | 62.0 k | 922.0 k | 679.8 k | esef· 27 May 2025verified |
| Current assets | 2.6 m | 2.2 m | 839.0 k | esef· 27 May 2025verified |
| Property, plant & equipment, net | 1.0 m | 966.4 k | 759.4 k | esef· 27 May 2025verified |
| Intangibles (excl. goodwill) | 441.5 k | 470.2 k | 477.4 k | esef· 27 May 2025verified |
| Total assets | 7.1 m | 6.1 m | 4.2 m | esef· 27 May 2025verified |
| Accounts payable | 426.3 k | 379.0 k | 735.0 k | esef· 27 May 2025verified |
| Current liabilities | 748.4 k | 741.5 k | 1.2 m | esef· 27 May 2025verified |
| Total liabilities | 3.8 m | 3.3 m | 3.4 m | esef· 27 May 2025verified |
| Equity | 3.2 m | 2.8 m | 853.5 k | esef· 27 May 2025verified |
Cash flow · GBP
| Line | 2022 | 2023 | 2024 | Source (latest year) |
|---|---|---|---|---|
| Operating cash flow | -2.9 m | -6.1 m | -4.1 m | esef· 27 May 2025verified |
| Capex | 428.9 k | 117.3 k | 13.3 k | esef· 27 May 2025verified |
| Free cash flow | -3.3 m ≈ | -6.2 m ≈ | -4.2 m ≈ | esef· 27 May 2025derived |
| Investing cash flow | -420.3 k | -31.9 k | -1.7 k | esef· 27 May 2025verified |
| Financing cash flow | -110.1 k | 4.4 m | 3.1 m | esef· 27 May 2025verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 2 of at least 6
- score weight coverage: 10.4% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
05 Nov 2026Source: olivLaw, closing series
Market cap: unavailable
Key indicators
Coverage and freshness
The data is older than the freshness threshold.
Score by group
10% · Insufficient data
Estimated value range
unavailable — no valuation assumptions for the reporting currency
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
Assumptions (illustrative, editorial)
- Risk-free rate
- 6.5%
- Equity risk premium
- 6.0%
- Beta (default)
- 1.00
- Cost of equity
- 12.5%
- Terminal growth
- 3.0%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 2 of at least 6; score weight coverage: 10.4% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | unavailable | unavailable | — |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | unavailable | unavailable | — |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | 19.8x | 100 (on a fixed band) | 60% |
| Current ratio · Balance sheet | 0.7x | 0 (on a fixed band) | 40% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | unavailable | unavailable | — |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet60/100 · 2/3 factors with a value
- Growth· partialunavailable · 0/2 factors with a value
- Quality· partialunavailable · 0/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partialunavailable · 0/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
HEMOGENYX PHARMACEUTICALS PLC (HEMO.L). Latest full fiscal year: 2024; data up to 2024-12-31.
Figures computed from the financial statements: revenue 0 GBP in 2024; ROE -302.4%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 2 of at least 6; score weight coverage: 10.4% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Interest coverage: 19.8x
What contradicts it
- Current ratio: 0.7x
Not assessed (insufficient data or a ratio without meaning): ROIC, Net margin, FCF conversion, Revenue CAGR 3Y, EPS CAGR 3Y, Net debt / EBITDA, P/E (TTM), EV/EBITDA, FCF yield, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Listed companies from United Kingdom · same country · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| BATS.LBritish American Tobacco P.L.C. | 104.3 bn | 13.5 | 16.5% | 30.3% | −1.0% | +7% / +88% |
| ABF.LAssociated British Foods PLC | 14.7 bn | 14.3 | 9.2% | 5.3% | −3.1% | −5% / −15% |
| 0EV1.LCarnival PLC | 5.5 bn | 4.1 | 46.7% | 13.4% | +6.4% | unavailable / unavailable |
| BAB.LBabcock International Group PLC | 5.1 bn | 24.7 | 34.7% | 4.1% | +7.2% | −10% / +158% |
| AUTO.LAutotrader Group PLC | 4.8 bn | 16.4 | 60.2% | 47.1% | +3.9% | −13% / −23% |
| BBY.LBalfour Beatty PLC | 4.2 bn | 16.3 | 23.2% | 2.8% | +15.2% | +20% / +160% |
| ABDN.LAberdeen Group PLC | 4.1 bn | 10.8 | 8.0% | 28.9% | −2.1% | +11% / +41% |
| BKG.LThe Berkeley Group Holdings PLC | 3.6 bn | 11.3 | 8.8% | 13.4% | −4.2% | −0% / −22% |
| BME.LB&M European Value Retail PLC | 2.9 bn | 17.4 | 21.2% | 2.8% | +3.7% | +68% / −51% |
| AJB.LAj Bell PLC | 2.4 bn | 22.8 | 49.9% | 33.1% | +18.0% | +8% / +128% |
| ASHM.LAshmore Group PLC | 1.4 bn | 13.9 | 13.1% | 71.6% | −0.1% | +28% / +18% |
| BCG.LBaltic Classifieds Group PLC | 1.2 bn | 23.2 | 15.8% | 57.6% | +6.9% | −99% / −99% |
| APN.LApplied Nutrition PLC | 763.6 m | 36.2 | 41.2% | 19.7% | +24.2% | +71% / unavailable |
| BAG.LA.G. Barr P.L.C. | 671.9 m | 14.4 | 14.4% | 10.8% | +4.0% | −7% / +26% |
| ASC.LAsos PLC | 494.5 m | — | -81.3% | -12.0% | −14.7% | +71% / +8% |
| ALFA.LAlfa Financial Software Holdings PLC | 486.8 m | 16.3 | 61.5% | 23.8% | +15.3% | −28% / +10% |
| AML.LAston Martin Lagonda Global Holdings PLC | 344.3 m | — | -93.4% | -39.2% | −20.6% | −45% / −85% |
| APTD.LAptitude Software Group PLC | 111.3 m | 28.5 | 7.2% | 6.2% | −7.3% | −30% / −23% |
| AMGO.LAmigo Holdings PLC | 9.9 m | — | — | — | −81.9% | +325% / +844% |
| ASBE.LAssociated British Engineering PLC | 605.3 k | — | -19.1% | — | unavailable | unavailable / unavailable |
| AMIF.LAmicorp Fs (uk) PLC | 221.6 k | 0.1 | 27.5% | 9.1% | +8.1% | unavailable / unavailable |
| AAF.LAirtel Africa PLC | — | — | 24.1% | 10.6% | +29.5% | −7% / +164% |
| AAL.LAnglo American PLC | — | — | -19.3% | -20.2% | +4.5% | +30% / +76% |
| ACG.LAcg Metals Limited | — | — | -80.3% | -32.0% | +134.8% | +60% / +63% |
| AEP.LAnglo-Eastern Plantations PLC | — | — | 16.1% | 19.5% | +25.0% | +5% / +113% |
1- and 3-year price returns: for HEMO.L from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Scenarios are not available. input data missing
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
Hemogenyx Pharmaceuticals plc is a London-listed biotechnology company developing products for acute myeloid leukaemia, blood disorders and viral infections, with its main laboratory in New York. The company has no commercial sales yet, and its net loss for 2024 was 5.6 million pounds sterling 1.
SWOT
Strengths
- The company holds several patents granted in the United States and other territories that protect its proprietary technologies 1.
- Its products address an important medical need and could replace current methods with severe side effects 1.
- The advisory board includes specialists with experience in clinical development and commercialisation of cancer treatments 1.
Weaknesses
Opportunities
- If clinical studies confirm preclinical results, the products could access large haematology oncology markets 1.
- The CBR platform and AHC models could generate collaborations with other pharmaceutical companies for testing and development 1.
- Extending intellectual property through new patent applications could strengthen the company's long-term position 1.
Threats
- Clinical study failures or regulatory approval delays could postpone or prevent commercialisation 1.
- Competitors with greater resources or further clinical progress could reduce the chances of the company's products succeeding 1.
- Difficult capital market conditions could limit access to funding and lead to dilution of shareholders 1.
Risks
- Uncertain commercial developmenthigh
The group has no sales yet, and reaching commercialisation depends on factors largely outside its control, including regulatory approvals 1.
- Uncertain clinical resultshigh
Results from preclinical and early studies do not guarantee success in later phases, and failure can occur at any stage 1.
- Need for further financinghigh
Product development depends on new equity raises, and a lack of funding could call into question the company's ability to continue 1.
- Dependence on key personnelmedium
The group's activity depends on a few essential management members, and losing them could adversely affect results 1.
- Intellectual property risksmedium
The company could become involved in litigation over its own or others' intellectual property, and its Hu-PHEC licence depends on meeting development milestones 1.
Investment thesis
What would need to be true (bull case)
- If HG-CT-1 and the CDX antibodies confirm their efficacy in clinical studies, the company could become a relevant player in treating acute myeloid leukaemia 1.
- Its platform technologies and patent portfolio could attract collaborations with large pharmaceutical companies, reducing dependence on equity funding 1.
- The haematology oncology market is large, and a product that replaces current transplant preparation methods could have a significant commercial impact 1.
What would break the thesis
- The company has no sales and makes losses each year, and most products are at early stages where failure is common 1.
- Dependence on new share issues could lead to significant dilution of existing shareholders if funding becomes more expensive or harder to obtain 1.
- Larger and more advanced competitors could reach the market first, reducing the chances that the company's products gain a significant position 1.
What to watch
- Progress of clinical studies for HG-CT-12025
- New share issues and how the company funds itself2025
- Developments in collaborations with pharmaceutical companies for the CBR and AHC platformsnext annual report
- Any newly granted patents or published patent applicationsnext annual report
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
The group focuses on discovering, developing and commercialising products to address blood disorders such as cancers and autoimmune diseases, as well as viral infections 1. Its lead product, HG-CT-1, is a CAR-T cell therapy for acute myeloid leukaemia and is in clinical trials 1. The company also has two platform technologies, the ApbHC humanised mouse models and the Chimeric Bait Receptors CBR 1.
The group's principal laboratory is in Manhattan, New York, and two of its companies are located outside the UK 1. The shares were admitted to the London Stock Exchange as Silver Falcon plc in 2015 and renamed Hemogenyx Pharmaceuticals plc in 2017 after the acquisition of Hemogenyx Pharmaceuticals Limited 1.
Management consists of the founder and chief executive, a chairman who also runs the advisory board, and advisers with clinical and regulatory experience 1. The strategy relies on intellectual property, with several patents granted or pending in the United States, China and through international applications 1.
Segments
CAR-T and CDX antibody therapies for leukaemia
HG-CT-1 modifies a patient's T-cells to recognise and kill cancer cells, while CDX bi-specific antibodies aim to eliminate haematopoietic stem cells before transplantation 1. If preclinical results are confirmed, these products could replace chemotherapy and radiation as preparation for transplant 1.
CBR platform and AHC models
The CBR platform aims to programme immune cells to destroy viruses and potentially certain cancers or neurological conditions, while the AHC humanised mice are used to model disease and test antibodies 1. These platforms are mainly at the preclinical stage, although some collaborations with pharmaceutical companies have already taken place 1.
Market context
The company operates in the market for oncology and haematology therapies, where monoclonal antibodies already generate very large worldwide sales, such as trastuzumab, which exceeds 6.5 billion dollars a year 1. The company is at an early stage with no commercial sales, and success depends on regulatory approvals in various territories 1.
The market for cell therapies and immunotherapies for leukaemia is developing quickly, and small companies depend on partnerships and equity financing to continue their studies 1. A possible success could open access to major markets, but manufacturing and commercialisation costs remain uncertain 1.
Trends
- Progress of CAR-T clinical studiestailwind
If HG-CT-1 advances through clinical trials, the company could demonstrate the value of its product, which would support investor and partner interest 1.
- Reliance on equity financingheadwind
Developing products to sale depends on the group's ability to obtain funds, mainly through new share issues, which could dilute existing shareholders 1.
- Interest in cancer immunotherapymixed
Growing interest in cell therapies against cancer could facilitate collaborations and funding, although competitive pressure remains high 1.
- International trade environmentheadwind
Changes in trade and regulation between states could impose unexpected costs or non-tariff barriers, although the company monitors these risks 1.
Competitive position
The company competes with other organisations, some with greater resources or a more established presence in certain territories 1. Competition is especially intense in CAR-T therapies and transplant preparation for leukaemia, where several companies develop similar products 1.
An advantage could come from its own intellectual property and platform technologies, but these must still be validated through studies 1. If clinical results are confirmed, the company could hold a distinct position, although development uncertainties remain significant 1.
- Eli Lilly & CompanyLLY
Collaboration partner with which the company discovered and validated anti-FLT3/CD3 antibodies 1.
- Kiadis Pharma
Company that acquired NewBiotics, founded by the company's scientific adviser, active in the same cell therapy field 1.
- Symphogen
Company that acquired BioLogix, founded by the company's scientific adviser, active in biotechnology 1.
- Developers of CAR-T therapies for leukaemia
Cell therapy developers targeting the same patient group, whose products are more advanced clinically 1.
News & filings
In the press
No news in our archive over the last 180 days.
Annual reports (ESEF)
- Annual report 202427 May 2025
- Annual report 202302 May 2024
Sources
- [1] Annual report, fiscal year ended 2024-12-31 (ESEF) · SEC / Hemogenyx Pharmaceuticals plc · 31 Dec 2024
Figures computed by olivLaw from ESEF annual reports and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.